Core Insights - AngioDynamics is undergoing a significant transformation to shift from a traditional device manufacturer to a focused MedTech company targeting large addressable markets with high gross margins [2][3] Company Overview - AngioDynamics operates on a unique fiscal year that begins on June 1, with the second quarter of FY 2026 nearing completion in three weeks [2] - The company has spent the last five years restructuring its portfolio to enhance competitiveness and focus on areas where it can achieve success [2][3]

Summary of AngioDynamics Conference Call Company Overview - **Company**: AngioDynamics (NasdaqGS: ANGO) - **Fiscal Year**: The company operates on a unique fiscal year starting June 1, currently nearing the end of Q2 for FY 2026 - **Transformation**: AngioDynamics is undergoing a transformation from a diversified medical device company to a focused MedTech company targeting large addressable markets with high gross margins [4][6][8] Key Points on Transformation and Financial Performance - **Revenue Shift**: The MedTech business has grown from less than 17% of total revenue to approximately 45%, with expectations to surpass 50% soon [8][10] - **EBITDA Positive**: The company achieved adjusted EBITDA positivity last fiscal year and expects to maintain this going forward [8][10] - **Cash Flow**: AngioDynamics anticipates being cash flow positive for the fiscal year ending May 31 [9][10] - **Growth Rate**: The MedTech segment has experienced a compound annual growth rate (CAGR) of about 25% over the last five years [12] MedTech Business Insights - **Market Focus**: The MedTech portfolio includes two cardiovascular areas and one interventional oncology area, with significant growth potential in each [14][15] - **Key Products**: - **NanoKnife**: Recently approved for treating intermediate-risk prostate cancer, with a market potential of over $2 billion globally [14][15][75] - **Arion System**: Launched in 2020, it has grown to over $60 million in revenue, focusing on peripheral arterial disease (PAD) [6][43] - **AlphaVac System**: Competing in the venous thromboembolism (VTE) market, showing a 40% growth in Q1 [20][21] Market Dynamics and Growth Drivers - **Interventional Oncology**: The NanoKnife product addresses a significant market need, with a focus on preserving quality of life for patients [78][80] - **Cardiovascular Market**: The company is expanding into coronary interventions, which represent a larger market opportunity [15][46] - **VTE Market**: The mechanical thrombectomy market is expected to grow, with AngioDynamics taking market share from competitors [20][23] Challenges and Opportunities - **Macro Environment**: The healthcare sector faces pressures from Medicare and Medicaid changes, but AngioDynamics believes its product mix positions it well to navigate these challenges [17][18] - **Clinical Evidence**: Ongoing studies and clinical data generation are crucial for market adoption and confidence in mechanical thrombectomy and other products [25][41][58] Financial Outlook - **Sales Growth Guidance**: For FY 2026, AngioDynamics projects overall sales growth of 5-7%, with double-digit growth expected in the MedTech segment [94][98] - **Capital Allocation**: The company plans to focus on innovation within its existing MedTech business rather than pursuing external M&A in the near term [91][93] Conclusion - AngioDynamics is strategically positioned for growth in the MedTech sector, with a strong focus on innovation, clinical evidence, and market expansion. The company is optimistic about its financial trajectory and the potential for its products to capture significant market share in the coming years [84][88][90]

Core Insights - AngioDynamics, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, with CEO Jim Clemmer and CFO Stephen Trowbridge presenting [1] - The company's NanoKnife System has been recognized as one of TIME's 2025 Best Inventions, highlighting its innovative impact on healthcare [6] Financial Performance - For the first quarter of fiscal year 2026, AngioDynamics reported net sales of $75.7 million, reflecting a year-over-year growth of 26.1% in the medical technology sector [7]

Core Insights - AngioDynamics, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, with CEO Jim Clemmer and CFO Stephen Trowbridge presenting [1] - The company's NanoKnife System has been recognized as one of TIME's 2025 Best Inventions, highlighting its innovative impact in medical technology [6] - AngioDynamics reported a net sales figure of $75.7 million for the first quarter of fiscal year 2026, reflecting a year-over-year growth of 26.1% in the medical technology sector [7] Company Overview - AngioDynamics is a medical technology company focused on restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life [3][6] - The company’s innovative technologies are utilized by physicians in rapidly growing healthcare markets to address unmet patient needs [3] Financial Performance - For the first quarter of fiscal year 2026, which ended on August 31, 2025, AngioDynamics achieved net sales of $75.7 million, indicating strong growth in the medical technology sector [7]

Core Insights - AngioDynamics, Inc. (NASDAQ:ANGO) is highlighted as a small-cap stock with significant upside potential, supported by a Buy rating from H.C. Wainwright and a price target of $16 following strong fiscal Q1 2026 results [1][2]. Financial Performance - The company reported net sales of $75.7 million for Q1 2026, reflecting a year-over-year increase of 12.2%, primarily driven by a 26.1% rise in Med Tech revenue [2]. - Key products, AlphaVac and AngioVac, experienced substantial sales growth, with increases of over 50% and 37% respectively, contributing to a 91% stock return over the past year [2]. - Despite a net loss of $10.9 million, AngioDynamics achieved a positive adjusted EBITDA of $2.2 million [3]. - U.S. and international sales grew by 11.7% and 15.6%, respectively [3]. - The company raised its full-year guidance, projecting net sales between $308 million and $313 million, and adjusted EBITDA between $6.0 million and $10.0 million, while maintaining its gross margin outlook [3]. Company Overview - AngioDynamics is a global medical technology company that develops, produces, and markets devices for treating peripheral vascular disease, cancer, and surgical conditions, supporting both diagnostic and therapeutic procedures in U.S. and international healthcare markets [4].

Core Insights - AngioDynamics, Inc. reported a narrower-than-expected loss per share of $0.10 for Q1 fiscal 2026, surpassing the Zacks Consensus Estimate of a $0.14 loss, and showing improvement from the previous year's adjusted loss of $0.11 per share [1][6] - The company's revenue for the quarter was $75.71 million, slightly below the estimated $75.94 million, but still represents a 12.2% increase from the previous year, driven by a 26.1% increase in its Med Tech segment [2][6] - Following the earnings report, AngioDynamics raised its fiscal year 2026 sales outlook to a range of $308 million to $313 million, indicating confidence in continued growth [2][6] Financial Performance - The pro-forma adjusted figures showed a GAAP loss per share of $0.26, an improvement from the previous year's loss of $0.32, despite a negative price-to-earnings (P/E) ratio of -14.44 [3] - The company's gross profit margin increased to 55.3%, which is 90 basis points higher than the previous year, although GAAP-calculated earnings were lower than the adjusted profit of $0.10 per share [4] - AngioDynamics maintains a strong liquidity position with a current ratio of 2.29, indicating it has more than twice the amount of current assets compared to its current liabilities [3] Market Reaction - Following the earnings report, AngioDynamics' stock surged by 10.5% by 11:25 a.m. ET, reflecting investor confidence in the company's performance and future prospects [4] - Despite financial ratio challenges, such as a price-to-sales ratio of 1.53 and an enterprise value to operating cash flow ratio of -49.91, the company continues to focus on its core operations [5]

Core Insights - AngioDynamics, Inc. reported stronger-than-expected first-quarter results and raised its fiscal 2026 guidance, indicating growth across its Med-Tech businesses [1][3] Financial Performance - First-quarter revenue increased by 12.1% to $75.7 million, exceeding consensus estimates, driven by a 26.2% rise in Med-Tech sales [2] - Gross margin improved to 55.3%, surpassing the expected 52.5% [2] - Adjusted EPS showed a loss of 10 cents, slightly below forecasts, while adjusted EBITDA reached $2.2 million, exceeding estimates [2] Fiscal Guidance - Fiscal year 2026 revenue guidance was raised to between $308 million and $313 million, reflecting a projected Med-Tech growth of 14% to 16% [3] - Adjusted EBITDA is now expected to range from $6 million to $10 million, with positive cash flow anticipated for the year [3] - Gross margin guidance remains steady at 53.5%-55.5%, despite challenges from manufacturing transitions and raw material costs [3] Product Performance - Mechanical Thrombectomy revenue grew by 41.2% year-over-year to $11.3 million, with strong performance from AngioVac and AlphaVac [4] - Auryon generated $16.5 million in revenue, up 20.1% year-over-year, benefiting from expansion in outpatient labs and hospitals [5] - NanoKnife revenue reached $6.4 million, a 26.7% year-over-year increase, with disposables sales exceeding forecasts [5] Financial Position - AngioDynamics ended the quarter with $38.8 million in cash, no debt, and full access to a $25 million revolving credit facility [6] - Management anticipates approximately $3 million in cash burn in the second quarter before achieving positive cash flow in the second half [6] - Canaccord projects revenue of $310.9 million for fiscal year 2026 and $325.1 million for fiscal year 2027, slightly adjusted from previous estimates [6]

Core Insights - AngioDynamics, Inc. (ANGO) reported a pro-forma adjusted loss per share of 10 cents for the first quarter of fiscal 2026, an improvement from the adjusted loss of 11 cents in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 14 cents [1][7] - Pro-forma revenues for the fiscal first quarter reached $75.7 million, reflecting a year-over-year increase of 12.2% and surpassing the Zacks Consensus Estimate by 4.8% [3][7] - The company raised its fiscal 2026 sales outlook to a range of $308-$313 million, up from the previous guidance of $305-$310 million, driven by strong performance in the Med Tech segment [15][21] Revenue Performance - U.S. net revenues for the quarter totaled $66.5 million, up 11.7% year over year, exceeding the estimate of $62.3 million [6] - Pro-forma international revenues were $9.3 million, a 15.6% increase from the previous year, although below the projected $10.2 million [8] - The Med Tech segment's pro-forma net sales were $35.3 million, a 26.1% year-over-year increase, outperforming the estimate of $32.7 million [9][10] Segment Analysis - The growth in the Med Tech segment was primarily driven by increased sales of the Auryon platform, which generated $16.5 million (up 20.1% year over year), and Mechanical Thrombectomy revenues of $11.3 million (up 41.2% year over year) [10][19] - Pro-forma Med Device revenues totaled $40.5 million, reflecting a modest increase of 2.3% from the prior year, slightly above the estimate of $39.9 million [11] Margin and Expense Analysis - Pro forma gross profit rose 14% to $41.9 million, with the gross margin expanding by 90 basis points to 55.3%, surpassing the projected margin of 54.2% [12] - Sales and marketing expenses increased by 9.9% year over year to $28.1 million, while research and development expenses rose 2.1% to $6.4 million [13] Cash Position - AngioDynamics ended the first quarter of fiscal 2026 with cash and cash equivalents of $38.8 million, down from $55.9 million at the end of fiscal 2025, with no debt on its balance sheet [14] Future Outlook - The company expects Med Tech revenue growth to be in the range of 14-16%, up from the previous guidance of 12-15%, while Med Device revenue growth is projected to remain flat compared to fiscal 2025 [15] - Management anticipates a $4-$6 million impact from tariffs on overall performance, with adjusted loss per share projected between 33 cents and 23 cents [16]

[FORM 10-Q Filing Information](index=1&type=section&id=FORM%2010-Q%20Filing%20Information) This section details the registrant's identification, filing status, and common shares outstanding for the Form 10-Q filing [Registrant Information](index=1&type=section&id=Registrant%20Information) This section provides the basic identification details for AngioDynamics, Inc. as a registrant filing a Form 10-Q - AngioDynamics, Inc. is filing a Quarterly Report on Form 10-Q for the period ended August 31, 2025[2](index=2&type=chunk) - The company's principal executive offices are located at 14 Plaza Drive, Latham, New York 12110[3](index=3&type=chunk) [Filer Status and Shares Outstanding](index=2&type=section&id=Filer%20Status%20and%20Shares%20Outstanding) This section outlines the company's filer status and the number of common shares outstanding as of October 1, 2025 - The registrant is an **accelerated filer** and has filed all required reports during the preceding 12 months[4](index=4&type=chunk) Filer Status | Status | Checkmark | | :---------------------- | :-------- | | Large accelerated filer | ☐ | | Accelerated filer | ☒ | | Non-accelerated filer | ☐ | | Smaller reporting company | ☐ | | Emerging growth company | ☐ | Common Stock Outstanding | Class | Outstanding as of October 1, 2025 | | :---------------- | :-------------------------------- | | Common Stock, par value $.01 | 41,199,844 shares | [Part I: Financial Information](index=3&type=section&id=Part%20I%3A%20Financial%20Information) This part presents the unaudited consolidated financial statements and management's discussion and analysis of financial condition and results of operations [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited consolidated financial statements and related notes for AngioDynamics, Inc. and its subsidiaries [Consolidated Statements of Operations (unaudited)](index=4&type=section&id=Consolidated%20Statements%20of%20Operations%20%28unaudited%29) This statement provides a summary of the company's revenues, expenses, and net loss for the three months ended August 31, 2025 and 2024 Consolidated Statements of Operations (Three Months Ended August 31, in thousands) | Metric | Aug 31, 2025 | Aug 31, 2024 | Change ($) | Change (%) | | :-------------------- | :----------- | :----------- | :--------- | :--------- | | Net sales | $75,711 | $67,491 | $8,220 | 12.18% | | Gross margin | $41,857 | $36,724 | $5,133 | 13.98% | | Operating loss | $(10,656) | $(13,098) | $2,442 | -18.64% | | Net loss | $(10,903) | $(12,798) | $1,895 | -14.81% | | Basic loss per share | $(0.26) | $(0.31) | $0.05 | -16.13% | | Diluted loss per share| $(0.26) | $(0.31) | $0.05 | -16.13% | - Net sales increased by **12.18% to $75.7 million** for the three months ended August 31, 2025, compared to the same period in the prior year[10](index=10&type=chunk) - Net loss decreased by **14.81% to $10.9 million**, and diluted loss per share improved from $(0.31) to $(0.26) year-over-year[10](index=10&type=chunk) [Consolidated Statements of Comprehensive Loss (unaudited)](index=5&type=section&id=Consolidated%20Statements%20of%20Comprehensive%20Loss%20%28unaudited%29) This statement presents the net loss and other comprehensive income/loss components for the three months ended August 31, 2025 and 2024 Consolidated Statements of Comprehensive Loss (Three Months Ended August 31, in thousands) | Metric | Aug 31, 2025 | Aug 31, 2024 | Change ($) | Change (%) | | :-------------------- | :----------- | :----------- | :--------- | :--------- | | Net loss | $(10,903) | $(12,798) | $1,895 | -14.81% | | Foreign currency translation gain | $2,084 | $1,098 | $986 | 89.80% | | Total comprehensive loss, net of tax | $(8,819) | $(11,700) | $2,881 | -24.62% | - Foreign currency translation gain significantly increased by **89.8% to $2.1 million**, contributing to a reduced total comprehensive loss of **$(8.8) million** compared to $(11.7) million in the prior year[12](index=12&type=chunk) [Consolidated Balance Sheets (unaudited)](index=6&type=section&id=Consolidated%20Balance%20Sheets%20%28unaudited%29) This statement provides a snapshot of the company's assets, liabilities, and equity as of August 31, 2025, and May 31, 2025 Consolidated Balance Sheets (as of, in thousands) | Metric | Aug 31, 2025 | May 31, 2025 | Change ($) | Change (%) | | :-------------------- | :----------- | :----------- | :--------- | :--------- | | Cash and cash equivalents | $38,762 | $55,893 | $(17,131) | -30.65% | | Total current assets | $156,656 | $168,324 | $(11,668) | -6.93% | | Total assets | $265,642 | $280,144 | $(14,502) | -5.18% | | Total current liabilities | $68,282 | $76,197 | $(7,915) | -10.39% | | Total liabilities | $86,787 | $97,174 | $(10,387) | -10.69% | | Total Stockholders' Equity | $178,855 | $182,970 | $(4,115) | -2.25% | - Cash and cash equivalents decreased by **30.65% to $38.8 million** from May 31, 2025, impacting total current assets and total assets[14](index=14&type=chunk) - Total liabilities decreased by **10.69% to $86.8 million**, primarily due to a reduction in current liabilities[14](index=14&type=chunk) [Consolidated Statements of Cash Flows (unaudited)](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows%20%28unaudited%29) This statement details the cash inflows and outflows from operating, investing, and financing activities for the three months ended August 31, 2025 and 2024 Consolidated Statements of Cash Flows (Three Months Ended August 31, in thousands) | Cash Flow Activity | Aug 31, 2025 | Aug 31, 2024 | Change ($) | Change (%) | | :-------------------------------- | :----------- | :----------- | :--------- | :--------- | | Net cash used in operating activities | $(15,914) | $(18,253) | $2,339 | -12.81% | | Net cash used in investing activities | $(1,551) | $(2,405) | $854 | -35.51% | | Net cash provided by (used in) financing activities | $143 | $(509) | $652 | -128.09% | | Decrease in cash and cash equivalents | $(17,131) | $(21,051) | $3,920 | -18.62% | - Net cash used in operating activities decreased by **12.81% to $15.9 million**, primarily due to improved working capital management[17](index=17&type=chunk)[128](index=128&type=chunk) - Financing activities shifted from using $0.5 million cash in 2024 to providing **$0.1 million cash** in 2025, mainly due to proceeds from stock option exercises and reduced share repurchases[17](index=17&type=chunk)[128](index=128&type=chunk) [Consolidated Statements of Stockholders' Equity (unaudited)](index=8&type=section&id=Consolidated%20Statements%20of%20Stockholders'%20Equity%20%28unaudited%29) This statement outlines the changes in stockholders' equity for the three months ended August 31, 2025 and 2024 Changes in Stockholders' Equity (Three Months Ended August 31, 2025, in thousands) | Item | Balance at May 31, 2025 | Net Loss | Issuance/Cancellation of restricted stock units | Purchases of common stock under ESPP | Stock-based compensation | Other comprehensive income, net of tax | Balance at August 31, 2025 | | :------------------ | :---------------------- | :------- | :-------------------------------------------- | :----------------------------------- | :----------------------- | :----------------------------------- | :------------------------- | | Total | $182,970 | $(10,903) | $(478) | $712 | $4,470 | $2,084 | $178,855 | Changes in Stockholders' Equity (Three Months Ended August 31, 2024, in thousands) | Item | Balance at May 31, 2024 | Net Loss | Issuance/Cancellation of restricted stock units | Issuance/Cancellation of performance share units | Purchases of common stock under ESPP | Stock-based compensation | Common stock repurchased | Other comprehensive income, net of tax | Balance at August 31, 2024 | | :------------------ | :---------------------- | :------- | :-------------------------------------------- | :--------------------------------------------- | :----------------------------------- | :----------------------- | :----------------------- | :----------------------------------- | :------------------------- | | Total | $205,586 | $(12,798) | $(321) | $(347) | $711 | $3,205 | $(552) | $1,098 | $196,582 | - Total stockholders' equity decreased from **$182.97 million** at May 31, 2025, to **$178.86 million** at August 31, 2025, primarily due to the net loss, partially offset by stock-based compensation and other comprehensive income[19](index=19&type=chunk) [Notes to Consolidated Financial Statements (unaudited)](index=9&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements%20%28unaudited%29) This section provides detailed explanations and disclosures supporting the unaudited consolidated financial statements [1. CONSOLIDATED FINANCIAL STATEMENTS](index=9&type=section&id=1.%20CONSOLIDATED%20FINANCIAL%20STATEMENTS) This note describes the basis of presentation and consolidation principles for the interim financial statements - The interim consolidated financial statements are unaudited and include AngioDynamics, Inc. and its wholly-owned subsidiaries, with all intercompany balances and transactions eliminated[21](index=21&type=chunk)[22](index=22&type=chunk) - Management believes all necessary adjustments (normal recurring adjustments) have been made to fairly state the financial position, results of operations, and cash flows[21](index=21&type=chunk) [2. REVENUE FROM CONTRACTS WITH CUSTOMERS](index=9&type=section&id=2.%20REVENUE%20FROM%20CONTRACTS%20WITH%20CUSTOMERS) This note details the company's revenue recognition policies, disaggregated net sales, and contract balances - Revenue is primarily derived from product sales, recognized when control is transferred to the customer, typically upon shipment or delivery[24](index=24&type=chunk)[30](index=30&type=chunk) Net Sales by Segment and Geography (Three Months Ended August 31, in thousands) | (in thousands) | United States (2025) | International (2025) | Total (2025) | United States (2024) | International (2024) | Total (2024) | | :------------- | :------------------- | :------------------- | :----------- | :------------------- | :------------------- | :----------- | | Med Tech | $31,374 | $3,887 | $35,261 | $24,889 | $3,080 | $27,969 | | Med Device | $35,082 | $5,368 | $40,450 | $34,592 | $4,930 | $39,522 | | Total | $66,456 | $9,255 | $75,711 | $59,481 | $8,010 | $67,491 | Contract Balances with Customers (as of, in thousands) | (in thousands) | Aug 31, 2025 | May 31, 2025 | | :------------- | :----------- | :----------- | | Receivables | $42,643 | $42,890 | | Contract assets | $— | $— | | Contract liabilities | $320 | $277 | [3. INVENTORIES](index=11&type=section&id=3.%20INVENTORIES) This note provides information on inventory valuation methods and a breakdown of inventory categories and reserves - Inventories are valued at the lower of cost and net realizable value using the first-in, first-out (FIFO) method[39](index=39&type=chunk) Inventories (in thousands) | Category | Aug 31, 2025 | May 31, 2025 | | :-------------- | :----------- | :----------- | | Raw materials | $25,928 | $27,497 | | Work in process | $9,404 | $7,509 | | Finished goods | $26,923 | $27,000 | | Total Inventories | $62,255 | $62,006 | - The total inventory reserve for obsolescence, expiring, and slow-moving inventory increased from **$4.4 million** at May 31, 2025, to **$4.6 million** at August 31, 2025[39](index=39&type=chunk) [4. INTANGIBLE ASSETS](index=11&type=section&id=4.%20INTANGIBLE%20ASSETS) This note outlines the company's intangible assets, their amortization, and net carrying values - Intangible assets are amortized on a straight-line basis over estimated useful lives ranging from two to eighteen years[40](index=40&type=chunk) Intangible Assets, Net (in thousands) | Category | Aug 31, 2025 Net Carrying Value | May 31, 2025 Net Carrying Value | | :------------------ | :------------------------------ | :------------------------------ | | Product technologies | $65,411 | $66,016 | | Customer relationships | $2,834 | $2,947 | | Trademarks | $5 | $19 | | Licenses | $130 | $134 | | Total | $68,380 | $69,116 | - Amortization expense for the three months ended August 31, 2025, was **$2.7 million**, slightly up from $2.6 million in the prior year[41](index=41&type=chunk) [5. ACCRUED LIABILITIES](index=12&type=section&id=5.%20ACCRUED%20LIABILITIES) This note provides a detailed breakdown of the company's accrued liabilities as of August 31, 2025, and May 31, 2025 Accrued Liabilities (in thousands) | Category | Aug 31, 2025 | May 31, 2025 | | :---------------------------- | :----------- | :----------- | | Payroll and related expenses | $13,539 | $20,397 | | Outside services | $4,588 | $3,143 | | Research and development | $1,418 | $1,459 | | Royalties | $1,457 | $2,642 | | Sales and franchise taxes | $545 | $531 | | Deferred warranties | $292 | $374 | | Transaction service agreement payable | $674 | $2,241 | | Rebates | $468 | $446 | | Accrued freight | $575 | $575 | | Accrued severance | $887 | $800 | | Other | $3,214 | $2,910 | | Total | $27,657 | $35,518 | - Total accrued liabilities decreased from **$35.5 million** at May 31, 2025, to **$27.7 million** at August 31, 2025, primarily due to reductions in payroll and related expenses, royalties, and transaction service agreement payable[43](index=43&type=chunk) [6. LONG-TERM DEBT](index=13&type=section&id=6.%20LONG-TERM%20DEBT) This note describes the company's new secured revolving credit facility and its terms - The Company entered into a new **$25.0 million** secured revolving credit facility on May 28, 2025, with a two-year maturity[44](index=44&type=chunk)[45](index=45&type=chunk)[46](index=46&type=chunk) - As of August 31, 2025, there were **no amounts outstanding** on the Revolving Facility, and the carrying value of long-term debt approximated its fair market value[49](index=49&type=chunk) - The facility is secured by substantially all assets of the Loan Parties and Guarantors and includes a financial covenant requiring a fixed charge coverage ratio of not less than **1.05 to 1.00** after the Availability Block Period[47](index=47&type=chunk)[48](index=48&type=chunk) [7. INCOME TAXES](index=13&type=section&id=7.%20INCOME%20TAXES) This note discusses the company's effective tax rate and valuation allowance on deferred tax assets Effective Tax Rate (Three Months Ended August 31) | Metric | Aug 31, 2025 | Aug 31, 2024 | | :----- | :----------- | :----------- | | Estimated annual effective tax rate prior to discrete items | (0.6)% | 1.8% | | Effective tax rate including discrete items | (0.6)% | (1.1)% | - The Company maintains a **full valuation allowance** on its U.S. deferred tax assets due to not yet attaining a sustained level of profitability, meaning recent tax legislation (OBBBA) had no material impact on the financial statements for the quarter[52](index=52&type=chunk)[54](index=54&type=chunk) [8. SHARE-BASED COMPENSATION](index=14&type=section&id=8.%20SHARE-BASED%20COMPENSATION) This note details the share-based compensation expense and unrecognized compensation expense related to equity awards - Share-based compensation expense increased to **$4.5 million** for the three months ended August 31, 2025, from $3.2 million in the prior year[57](index=57&type=chunk) - As of August 31, 2025, **$28.4 million** of unrecognized compensation expense related to share-based payment arrangements is expected to be recognized over a weighted-average period of approximately three years[60](index=60&type=chunk) - The 2020 Stock and Incentive Award Plan had **2.5 million shares** available for future grants, and the employee stock purchase plan also had **2.5 million shares** available[55](index=55&type=chunk)[57](index=57&type=chunk) [9. EQUITY](index=14&type=section&id=9.%20EQUITY) This note provides information on the company's share repurchase program and its status - The Board of Directors approved a share repurchase program on July 16, 2024, authorizing up to **$15.0 million** in common stock repurchases[61](index=61&type=chunk) - No shares were repurchased during the first quarter of fiscal year 2026 (ended August 31, 2025), but **$0.5 million** was used to repurchase 72,141 shares in the first quarter of fiscal year 2025[61](index=61&type=chunk) - As of August 31, 2025, **$13.3 million** remained available for repurchase under the program[61](index=61&type=chunk) [10. EARNINGS PER SHARE](index=14&type=section&id=10.%20EARNINGS%20PER%20SHARE) This note explains the calculation of basic and diluted earnings per share and the impact of anti-dilutive securities - Basic earnings per share is calculated based on the weighted average number of common shares outstanding[62](index=62&type=chunk) - Diluted earnings per share includes the dilutive effect of potential common stock, but in periods with a net loss, such securities are excluded if their impact would be anti-dilutive[62](index=62&type=chunk) Weighted-Average Shares Outstanding (in thousands) | Category | Aug 31, 2025 | Aug 31, 2024 | | :------------------------------------------ | :----------- | :----------- | | Basic | 41,174 | 40,653 | | Effect of dilutive securities | — | — | | Diluted | 41,174 | 40,653 | | Securities excluded as their inclusion would be anti-dilutive | 6,183 | 5,180 | [11. SEGMENT AND GEOGRAPHIC INFORMATION](index=15&type=section&id=11.%20SEGMENT%20AND%20GEOGRAPHIC%20INFORMATION) This note provides disaggregated financial information by operating segment and geographic region - The Company operates through two segments: Med Tech (Auryon, thrombus management, NanoKnife) and Med Device (Core, Venous, Ports, other Oncology products)[65](index=65&type=chunk) Net Sales and Gross Margin by Segment (Three Months Ended August 31, in thousands) | Segment | Net Sales (2025) | Gross Margin (2025) | Gross Margin % (2025) | Net Sales (2024) | Gross Margin (2024) | Gross Margin % (2024) | | :--------------------- | :--------------- | :------------------ | :-------------------- | :--------------- | :------------------ | :-------------------- | | Med Tech | $35,261 | $21,922 | 62.2% | $27,969 | $17,697 | 63.3% | | Med Device | $40,450 | $19,935 | 49.3% | $39,522 | $19,027 | 48.1% | | Total | $75,711 | $41,857 | 55.3% | $67,491 | $36,724 | 54.4% | - International sales accounted for **12.2% of total net sales** in the three months ended August 31, 2025, up from 11.9% in the prior year[68](index=68&type=chunk) [12. FAIR VALUE](index=16&type=section&id=12.%20FAIR%20VALUE) This note discusses the fair value measurement of the company's financial instruments - The Company's financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, are measured at fair value, which approximates their carrying amount due to their immediate or short-term maturities[70](index=70&type=chunk) - The Company does not have assets or liabilities requiring recurring fair value measurement using significant unobservable inputs (Level 3)[70](index=70&type=chunk) [13. LEASES](index=16&type=section&id=13.%20LEASES) This note describes the company's operating leases and financing arrangements for facilities - The Company has operating leases for buildings and a financing arrangement for manufacturing and distribution facilities, which was accounted for as a financing arrangement rather than a sale-leaseback[71](index=71&type=chunk)[72](index=72&type=chunk)[73](index=73&type=chunk) Lease Liabilities (in thousands) | Category | Aug 31, 2025 | May 31, 2025 | | :---------------------------- | :----------- | :----------- | | Current operating lease liabilities | $1,773 | $1,840 | | Non-current operating lease liabilities | $1,725 | $2,106 | | Total lease liabilities | $3,498 | $3,946 | - Operating lease expense for the three months ended August 31, 2025, was **$0.6 million**, a slight decrease from $0.7 million in the prior year[79](index=79&type=chunk) [14. COMMITMENTS AND CONTINGENCIES](index=18&type=section&id=14.%20COMMITMENTS%20AND%20CONTINGENCIES) This note details the company's legal proceedings, including intellectual property disputes and product liability claims - The Company is involved in various legal proceedings, including intellectual property disputes with C.R. Bard, Inc. (now Becton, Dickinson and Company, 'BD') and approximately **219 product liability claims** related to its port products[80](index=80&type=chunk)[81](index=81&type=chunk)[83](index=83&type=chunk)[85](index=85&type=chunk) - A settlement agreement with BD was reached on March 31, 2024, involving a one-time lump sum payment of **$7.0 million** and minimum annual payments of **$2.5 million** starting in fiscal year 2025, with potential additional payments[84](index=84&type=chunk) - As of August 31, 2025, **$2.4 million** was payable to BD in current liabilities and **$6.7 million** in other long-term liabilities related to the settlement[84](index=84&type=chunk) [15. ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET](index=19&type=section&id=15.%20ACQUISITION%2C%20RESTRUCTURING%2C%20AND%20OTHER%20ITEMS%2C%20NET) This note provides a breakdown of acquisition, restructuring, and other net expenses, including plant closure costs Acquisition, Restructuring and Other Items, Net (in thousands) | Category | Three Months Ended Aug 31, 2025 | Three Months Ended Aug 31, 2024 | | :------------------------ | :------------------------------ | :------------------------------ | | Legal | $213 | $507 | | Plant closure | $2,345 | $3,589 | | Transition service agreement | $(302) | $(507) | | Other | $502 | $722 | | Total | $2,758 | $4,311 | - Total acquisition, restructuring, and other items, net, decreased by **$1.6 million** year-over-year, primarily due to lower plant closure expenses and legal costs[86](index=86&type=chunk)[121](index=121&type=chunk)[124](index=124&type=chunk) - The Company recorded **$2.3 million** in restructuring charges related to its manufacturing footprint optimization plan, with total charges to date reaching **$25.6 million** The plan is expected to be completed in Q3 fiscal year 2026[88](index=88&type=chunk)[89](index=89&type=chunk)[92](index=92&type=chunk) [16. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS](index=20&type=section&id=16.%20RECENTLY%20ISSUED%20ACCOUNTING%20PRONOUNCEMENTS) This note outlines the company's planned adoption of new accounting standards updates - The Company plans to adopt ASU 2023-09 (Income Tax Disclosures) for fiscal year 2026, ASU 2024-03 (Income Statement Expense Disaggregation) for fiscal year 2028, and ASU 2025-05 (Credit Losses for Accounts Receivable) for fiscal year 2027[95](index=95&type=chunk) - There have been **no material changes** to critical accounting policies since the Annual Report on Form 10-K for fiscal year ended May 31, 2025[95](index=95&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's analysis of the company's financial condition, operational results, and liquidity for the quarter [Disclosure Regarding Forward-Looking Statements](index=22&type=section&id=Disclosure%20Regarding%20Forward-Looking%20Statements) This section cautions that the report contains forward-looking statements subject to various risks and uncertainties - The report contains forward-looking statements subject to risks and uncertainties, and actual results may differ materially from expectations[98](index=98&type=chunk) - Factors affecting actual results include product development, competition, regulatory actions, economic conditions, litigation, and supply chain challenges[98](index=98&type=chunk) [Disclosure Regarding Trademarks](index=22&type=section&id=Disclosure%20Regarding%20Trademarks) This section clarifies the ownership and usage of trademarks, tradenames, and service marks within the report - The report includes trademarks, tradenames, and service marks that are property of AngioDynamics or third parties, and their omission of symbols does not waive rights[100](index=100&type=chunk) [Executive Overview](index=22&type=section&id=Executive%20Overview) This section provides a high-level summary of AngioDynamics' business, strategic focus, market dynamics, and key financial performance - AngioDynamics is a diversified medical technology company focused on cardiovascular disease and cancer, with a strategy built on R&D, clinical/regulatory expansion, and customer-centric sales[101](index=101&type=chunk) - The company's financial performance is influenced by market dynamics such as value-based purchasing, healthcare provider consolidation, and an aging population, as well as macroeconomic factors like inflation, labor shortages, and supply chain issues[102](index=102&type=chunk)[105](index=105&type=chunk) - Key financial metrics for the three months ended August 31, 2025, include a **12.2% revenue increase to $75.7 million**, with Med Tech growing **26.1%** and Med Device growing **2.3%**[106](index=106&type=chunk)[109](index=109&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) This section analyzes the company's net sales, gross margin, and operating expenses for the three months ended August 31, 2025 Net Sales by Segment (Three Months Ended August 31, in thousands) | Segment | Aug 31, 2025 | Aug 31, 2024 | $ Change | | :--------------------- | :----------- | :----------- | :------- | | Med Tech | $35,261 | $27,969 | $7,292 | | Med Device | $40,450 | $39,522 | $928 | | Total | $75,711 | $67,491 | $8,220 | - Med Tech net sales increased by **$7.3 million**, driven by Auryon, thrombus management platform, and NanoKnife sales[111](index=111&type=chunk)[113](index=113&type=chunk) - Total Company gross margin increased by **$5.1 million**, with gross margin percentage rising from **54.4% to 55.3%**, positively impacted by sales volume, price, and product mix[112](index=112&type=chunk)[114](index=114&type=chunk) Operating Expenses (Three Months Ended August 31, in thousands) | Expense | Aug 31, 2025 | Aug 31, 2024 | $ Change | | :--------------------- | :----------- | :----------- | :------- | | Research and development | $6,417 | $6,285 | $132 | | Sales and marketing | $28,130 | $25,605 | $2,525 | | General and administrative | $12,555 | $10,975 | $1,580 | | Amortization of intangibles | $2,653 | $2,570 | $83 | | Acquisition, restructuring and other items, net | $2,758 | $4,311 | $(1,553) | | Other expense, net | $(182) | $433 | $(615) | - Sales and marketing expense increased by **$2.5 million**, and general and administrative expense increased by **$1.6 million**, primarily due to higher compensation and benefits[117](index=117&type=chunk)[118](index=118&type=chunk)[119](index=119&type=chunk) [Liquidity and Capital Resources](index=26&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's cash position, cash flow activities, and its ability to meet future liquidity needs - Cash and cash equivalents decreased to **$38.8 million** as of August 31, 2025, from $55.9 million as of May 31, 2025[123](index=123&type=chunk) Cash Flows Summary (Three Months Ended August 31, in thousands) | Cash Flow Activity | Aug 31, 2025 | Aug 31, 2024 | | :-------------------------------- | :----------- | :----------- | | Operating activities | $(15,914) | $(18,253) | | Investing activities | $(1,551) | $(2,405) | | Financing activities | $143 | $(509) | | Net change in cash and cash equivalents | $(17,131) | $(21,051) | - The Company believes its current cash balance, cash from operations, and the Revolving Facility will provide sufficient liquidity for at least the next 12 months[126](index=126&type=chunk) [New Accounting Pronouncements](index=27&type=section&id=New%20Accounting%20Pronouncements) This section refers to the detailed information on recently issued accounting pronouncements in the financial statement notes - Information regarding new accounting pronouncements is detailed in Note 16 to the consolidated financial statements[127](index=127&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=28&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section details the company's exposure to market risks, including foreign currency, interest rate, and credit risk [Foreign Currency Exchange Rate Risk](index=28&type=section&id=Foreign%20Currency%20Exchange%20Rate%20Risk) This section analyzes the impact of foreign currency fluctuations on the company's profitability - Approximately **3.2% of sales** for the three months ended August 31, 2025, were denominated in foreign currencies (Euro, British Pound, Canadian Dollar), exposing profitability to currency fluctuations, particularly when the U.S. Dollar strengthens[130](index=130&type=chunk) [Interest Rate Risk](index=28&type=section&id=Interest%20Rate%20Risk) This section describes the company's exposure to interest rate fluctuations, primarily related to its debt facilities - The Company's interest rate risk is primarily limited to indebtedness; as of August 31, 2025, there was **no outstanding debt**[131](index=131&type=chunk)[132](index=132&type=chunk) - The **$25.0 million** secured revolving credit facility's interest rate is based on SOFR or ABR plus a margin, with a commitment fee on the unused portion[132](index=132&type=chunk) [Concentration of Credit Risk](index=28&type=section&id=Concentration%20of%20Credit%20Risk) This section addresses the company's credit risk exposure from cash and trade accounts receivable - Credit risk is concentrated in cash and cash equivalents (managed by evaluating financial institutions) and trade accounts receivable (limited by a large customer base, with no single customer exceeding **10% of total sales**)[133](index=133&type=chunk)[134](index=134&type=chunk) [Item 4. Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures) This section confirms the effectiveness of disclosure controls and reports no material changes in internal control over financial reporting - Management, including the CEO and CFO, concluded that disclosure controls and procedures were **effective** as of August 31, 2025, providing reasonable assurance for timely and accurate reporting[135](index=135&type=chunk) - There were **no material changes** in internal control over financial reporting during the fiscal quarter ended August 31, 2025[136](index=136&type=chunk) [Part II: Other Information](index=30&type=section&id=Part%20II%3A%20Other%20Information) This part includes information on legal proceedings, risk factors, equity sales, defaults, mine safety, and exhibits [Item 1. Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to the detailed disclosures on legal proceedings, commitments, and contingencies in the financial statement notes - Details regarding legal proceedings are provided in Note 14, 'Commitments and Contingencies,' within the consolidated financial statements[138](index=138&type=chunk) [Item 1A. Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors) This section directs readers to the annual report for risk factors and confirms no material changes since the last filing - Readers should refer to 'Part I, Item 1A. Risk Factors' in the annual report on Form 10-K for the fiscal year ended May 31, 2025, for important risks and uncertainties[139](index=139&type=chunk) - There have been **no material changes** to the risk factors previously disclosed in the annual report on Form 10-K[139](index=139&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=30&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details common stock repurchases for tax withholding and confirms no repurchases under the publicly announced program Issuer Purchases of Equity Securities (Three Months Ended August 31, 2025) | Period | Total Number of Shares Purchased (1) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs (2) | Maximum Approximate Dollar Value of Shares That May Yet Be Purchased Under Plans or Programs (2) | | :------------------------- | :----------------------------------- | :--------------------------- | :-------------------------------------------------------------------------- | :----------------------------------------------------------------------------------------------- | | June 1, 2025 - June 30, 2025 | 1,400 shares | $10.47 | — | — | | July 1, 2025 - July 31, 2025 | 53,006 shares | $9.15 | — | — | | August 1, 2025 - August 31, 2025 | — | $9.06 | — | — | | Total | 54,406 shares | $9.19 | — | — | - **54,406 shares** were purchased from employees to satisfy tax withholding requirements on the vesting of restricted shares/units from equity-based awards[144](index=144&type=chunk) - **No shares** were repurchased under the **$15.0 million** share repurchase program during the quarter ended August 31, 2025[140](index=140&type=chunk)[144](index=144&type=chunk) [Item 3. Defaults on Senior Securities](index=30&type=section&id=Item%203.%20Defaults%20on%20Senior%20Securities) This section confirms that the company reported no defaults on senior securities during the period - There were **no defaults** on senior securities[141](index=141&type=chunk) [Item 4. Mine Safety Disclosures](index=30&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section confirms that the company reported no mine safety disclosures - There were **no mine safety disclosures**[142](index=142&type=chunk) [Item 5. Other Information](index=30&type=section&id=Item%205.%20Other%20Information) This section confirms no Rule 10b5-1 trading arrangements were adopted or terminated by insiders or the company - **No Rule 10b5-1 trading arrangements** or non-Rule 10b5-1 trading arrangements were adopted or terminated by directors, officers, or the Company during the quarter ended August 31, 2025[143](index=143&type=chunk) [Item 6. Exhibits](index=31&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed as part of the Form 10-Q, including certifications and XBRL documents - The exhibit index includes certifications (Rule 13a-14(a), Section 1350) and XBRL documents (Schema, Calculation, Definition, Labels, Presentation Linkbase Documents)[145](index=145&type=chunk) [SIGNATURES](index=32&type=section&id=SIGNATURES) This section contains the official signatures of the company's principal executive and financial officers [Signatures](index=32&type=section&id=Signatures) This section contains the official signatures of the company's principal executive and financial officers as of October 2, 2025 - The report was signed by James C. Clemmer, President and Chief Executive Officer, and Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer, on October 2, 2025[148](index=148&type=chunk)

Core Viewpoint - The analysis indicates a positive outlook on AngioDynamics, Inc. (NASDAQ: ANGO) due to its expanding portfolio in medical technology, suggesting potential investment opportunities in the company [1]. Company Summary - AngioDynamics is recognized for its growth in the medical technology sector, which is often overlooked by many investors, particularly in the small- to mid-cap range [1]. - The company has been rated a Buy, reflecting confidence in its future performance and market position [1]. Industry Context - The analysis occasionally includes insights on large-cap companies to provide a broader perspective on equity markets, indicating that AngioDynamics operates within a competitive landscape that includes both small and large players [1].